logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Mei Pharma, Inc.


USPTO Granted Patents = 33

% Expired Patents = 42.4



Trademarks = 1

Forward Citations = 173

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Eric T Sun (9 out of 19 patents)

silverMedal Ofir Moreno (8 out of 17 patents)

bronzeMedal Andrew Heaton (7 out of 19 patents)

4.  S David Brown (6 out of 14 patents)

5.  David J Matthews (6 out of 23 patents)

6.  DiZhong Chen (6 out of 11 patents)

7.  Hong Yan Song (6 out of 8 patents)

8.  Niefang Yu (6 out of 8 patents)

9.  Yong Colin Zou (6 out of 33 patents)

10.  Daniel P Gold (4 out of 10 patents)

11.  Alan James Husband (4 out of 13 patents)

12.  George Jeoffreys (3 out of 4 patents)

13.  Alison Johnson (3 out of 4 patents)

14.  Haishan Wang (3 out of 7 patents)

15.  Ken Chi Lik Lee (3 out of 3 patents)


Core Competencies:
Voruciclib
Polymorphs
Isoflavonoid Compounds
Combination Therapy
Benzimidazole Derivatives
Chroman Derivatives
Imidazo[1,2-a]Pyridine
Proliferative Diseases
Pharmaceutical Applications
Medicaments

33 patents:

1. 12421216 - Voruciclib polymorphs and methods of making and using thereof (2025-09-23),
2. 12161644 - Combination therapy (2024-12-10),
3. 12059422 - (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases (2024-08-13),
4. 11723893 - Isoflavonoid compositions and methods for the treatment of cancer (2023-08-15),
5. 11583514 - Isoflavonoid compounds and methods for the treatment of cancer (2023-02-21),
6. 11400097 - (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases (2022-08-02),
7. 11351176 - Combination therapy (2022-06-07),
8. 11304953 - Combination therapy (2022-04-19),
9. 10980774 - Combination therapies (2021-04-20),
10. 10973799 - Isoflavonoid compositions and methods for the treatment of cancer (2021-04-13),
11. 10736881 - Benzimidazole derivatives: preparation and pharmaceutical applications (2020-08-11),
12. 10626092 - Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof (2020-04-21),
13. 10603324 - (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases (2020-03-31),
14. 10369132 - Isoflavonoid compositions and methods for the treatment of cancer (2019-08-06),
15. 10335415 - (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases (2019-07-02),
Mei Pharma, Inc. is a biotechnology company based in San Diego, California, focused on developing novel therapies for cancer and other serious diseases. The company specializes in the discovery and advancement of innovative drug candidates, particularly in the areas of oncology and hematology. With a commitment to addressing unmet medical needs, Mei Pharma leverages its proprietary technologies to create targeted treatments that aim to improve patient outcomes and enhance the quality of life for individuals battling complex health challenges.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Mei Pharma, Inc.
33 Patents

#192 in San Diego, CA

#2,460 in California

#10,297 in US

#20,130 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Mei Pharma, Inc.

Forward Citations = 173

17 inventors:

goldMedal Eric T Sun (9 out of 19 patents)

silverMedal Ofir Moreno (8 out of 17 patents)

bronzeMedal Andrew Heaton (7 out of 19 patents)

4.  S David Brown (6 out of 14 patents)

5.  David J Matthews (6 out of 23 patents)

Please report any incorrect information to [email protected]
Loading…